TW467892B - Substituted oxobutyric acids as matrix metalloprotease inhibitors - Google Patents

Substituted oxobutyric acids as matrix metalloprotease inhibitors Download PDF

Info

Publication number
TW467892B
TW467892B TW086106284A TW86106284A TW467892B TW 467892 B TW467892 B TW 467892B TW 086106284 A TW086106284 A TW 086106284A TW 86106284 A TW86106284 A TW 86106284A TW 467892 B TW467892 B TW 467892B
Authority
TW
Taiwan
Prior art keywords
group
carbon atoms
patent application
compound
alkyl
Prior art date
Application number
TW086106284A
Other languages
English (en)
Chinese (zh)
Inventor
Zandt Michael C Van
David R Brittelli
Brian R Dixon
Jinshan Chen
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of TW467892B publication Critical patent/TW467892B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
TW086106284A 1996-05-15 1997-05-12 Substituted oxobutyric acids as matrix metalloprotease inhibitors TW467892B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64838496A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
TW467892B true TW467892B (en) 2001-12-11

Family

ID=24600568

Family Applications (1)

Application Number Title Priority Date Filing Date
TW086106284A TW467892B (en) 1996-05-15 1997-05-12 Substituted oxobutyric acids as matrix metalloprotease inhibitors

Country Status (18)

Country Link
EP (1) EP0912487A1 (xx)
JP (1) JP3417951B2 (xx)
CN (1) CN1163466C (xx)
AR (1) AR007096A1 (xx)
AU (1) AU727648B2 (xx)
CA (1) CA2253869C (xx)
CO (1) CO4990925A1 (xx)
HR (1) HRP970246B1 (xx)
ID (1) ID20291A (xx)
MY (1) MY132470A (xx)
PA (1) PA8429401A1 (xx)
PE (1) PE65998A1 (xx)
SV (1) SV1997000034A (xx)
TN (1) TNSN97085A1 (xx)
TW (1) TW467892B (xx)
WO (1) WO1997043238A1 (xx)
YU (1) YU18797A (xx)
ZA (1) ZA974032B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
JP5263548B2 (ja) * 2007-08-15 2013-08-14 杏林製薬株式会社 イブジラストを有効成分とする脳動脈瘤の予防、形成抑制又は治療剤
CA2944614A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases
EP3126339A1 (de) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
JP2017511319A (ja) 2014-04-03 2017-04-20 バイエル ファーマ アクチエンゲゼルシャフト キラル２，５−ジ置換されたシクロペンタンカルボン酸誘導体およびそれの使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970700652A (ko) * 1994-01-22 1997-02-12 포올 리틀우드 금속단백질 분해효소 억제제

Also Published As

Publication number Publication date
ZA974032B (en) 1998-02-19
WO1997043238A1 (en) 1997-11-20
MY132470A (en) 2007-10-31
CN1225622A (zh) 1999-08-11
AU3121997A (en) 1997-12-05
JP3417951B2 (ja) 2003-06-16
AR007096A1 (es) 1999-10-13
SV1997000034A (es) 1999-07-05
CA2253869C (en) 2003-04-22
PA8429401A1 (es) 2000-05-24
CA2253869A1 (en) 1997-11-20
CN1163466C (zh) 2004-08-25
AU727648B2 (en) 2000-12-21
CO4990925A1 (es) 2000-12-26
EP0912487A1 (en) 1999-05-06
PE65998A1 (es) 1998-10-20
ID20291A (id) 1998-11-19
HRP970246A2 (en) 1998-04-30
TNSN97085A1 (fr) 2005-03-15
YU18797A (en) 1999-11-22
JPH11509870A (ja) 1999-08-31
HRP970246B1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
JPH01160992A (ja) 新規化合物、その製法及びそれを含む医薬組成物
US5925637A (en) Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids
AU714207B2 (en) Inhibition of matrix metalloproteases by 2-substituted-4- (4-substitutedphenyl)-4-oxobutyric acids
TW467892B (en) Substituted oxobutyric acids as matrix metalloprotease inhibitors
TW464642B (en) Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors
TW381079B (en) Biaryl acetylenes as inhibitors of matrix metalloproteases
JP3305328B2 (ja) 置換フェンアルキル化合物によるマトリックスプロテアーゼの阻害
TW442468B (en) Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors
TW457231B (en) Inhibition of matrix metalloproteases by 2(ω-aroylalkyl)-4-biaryl-4-oxobutyric
US5804581A (en) Inhibition of matrix metalloproteases by substituted phenalkyl compounds
US5932577A (en) Substituted oxobutyric acids as matrix metalloprotease inhibitors

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees